Erdafitinib Intravesical Delivery System

DRUG2 trials

Sponsors

Janssen Research & Development, LLC, Janssen Pharmaceutical K.K.

Conditions

Non-Muscle Invasive Bladder NeoplasmsReceptors, Fibroblast Growth FactorUrinary Bladder Neoplasms

Phase 1

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Active, not recruitingNCT05316155

Janssen Research & Development, LLCNon-Muscle Invasive Bladder Neoplasms

Start: 2022-04-11End: 2029-07-24Updated: 2026-08-28

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

Active, not recruitingNCT05567185

Janssen Pharmaceutical K.K.Receptors, Fibroblast Growth Factor, Urinary Bladder Neoplasms

Start: 2023-03-03End: 2026-08-30Updated: 2026-08-28

Related Papers

PD48-02 FIRST SAFETY AND EFFICACY RESULTS OF THE TAR-210 ERDAFITINIB INTRAVESICAL DELIVERY SYSTEM IN PATIENTS WITH NON–MUSCLE-INVASIVE BLADDER CANCER WITH SELECT <i>FGFR</i> ALTERATIONS

The Journal of Urology2024-04-154 citations

Urine-based testing for patient selection and genomic characterization of patients with <i>FGFR</i> alteration-positive non–muscle-invasive bladder cancer (NMIBC) treated with TAR-210.

Journal of Clinical Oncology2024-01-291 citations

Development of a novel RNA-based fibroblast growth factor receptor response signature (FGFR-PRS) for use in patients with urothelial cancer (UC).

Journal of Clinical Oncology2024-01-29

Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select <i>FGFR</i> mutations or fusions: Phase 1 first-in-human study.

Journal of Clinical Oncology2023-02-2012 citations